Literature DB >> 21207049

A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration.

Stefan Poljansky1, Bernd Ibach, Barbara Hirschberger, Peter Männer, Hans Klünemann, Göran Hajak, Jörg Marienhagen.   

Abstract

This study presents a visual rating scale for the assessment of cerebral [(18)F]fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) scans to characterize typical findings in dementias associated with frontotemporal lobar degeneration (FTLD) and to differentiate individual patients with FTLD compared to Alzheimer's disease (AD) and mild cognitive impairment (MCI). A total of 43 cerebral PET scans from patients with FTLD (n = 16, mean age 58.4 years), AD (n = 16, 59.9 years) and MCI (n = 11, 57.9 years) were analysed. Every PET data set was visually rated for seven brain regions on each hemisphere (frontal lobe, temporal lobe, parietal lobe, occipital lobe, basal ganglia, thalamus and cerebellum). The extent of the impairment in metabolism was classified as absent, mild, medium or strong. Using this four-stage visual rating scale, characteristic profiles of metabolic impairment in FTLD, AD, MCI and the FTLD-subgroup FTD (n = 9) could be demonstrated. Patients with FTLD showed a significantly lower metabolism in the left frontal lobe and in the left basal ganglia when compared to AD and to MCI. Complementary analyses using statistical parametric mapping (SPM2) supported the findings of the visual analysis. In detecting FTLD with visual rating, sensitivity/specificity was 81/94% compared to AD and 81/64% compared to MCI. Patients with FTD were correctly attributed to a diagnosis of FTLD with a sensitivity of 89%. This visual rating scale may facilitate the differential diagnosis of FTLD in clinical routine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21207049     DOI: 10.1007/s00406-010-0184-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  48 in total

1.  What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment.

Authors:  Katie Palmer; Laura Fratiglioni; Bengt Winblad
Journal:  Acta Neurol Scand Suppl       Date:  2003

2.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

3.  Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations.

Authors:  M Bibl; B Mollenhauer; S Wolf; H Esselmann; P Lewczuk; J Kornhuber; J Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2007-01-25       Impact factor: 3.575

4.  Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to (99m)Tc HmPAO SPECT data.

Authors:  P Charpentier; I Lavenu; L Defebvre; A Duhamel; P Lecouffe; F Pasquier; M Steinling
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

5.  18F-FDG PET findings in frontotemporal dementia: an SPM analysis of 29 patients.

Authors:  Yong Jeong; Sang Soo Cho; Jung Mi Park; Sue J Kang; Jae Sung Lee; Eunjoo Kang; Duk L Na; Sang Eun Kim
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

6.  The Bayer Activities of Daily Living Scale (B-ADL).

Authors:  I Hindmarch; H Lehfeld; P de Jongh; H Erzigkeit
Journal:  Dement Geriatr Cogn Disord       Date:  1998       Impact factor: 2.959

Review 7.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

9.  Brain metabolism in the cerebellum and visual cortex correlates with neuropsychological testing in patients with Alzheimer's disease.

Authors:  A Newberg; A Cotter; M Udeshi; F Brinkman; G Glosser; A Alavi; C Clark
Journal:  Nucl Med Commun       Date:  2003-07       Impact factor: 1.690

Review 10.  Alzheimer disease: operating characteristics of PET--a meta-analysis.

Authors:  Meenal B Patwardhan; Douglas C McCrory; David B Matchar; Gregory P Samsa; Olivier T Rutschmann
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

View more
  10 in total

Review 1.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

Review 2.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 3.  Multimodality imaging of Alzheimer disease and other neurodegenerative dementias.

Authors:  Ilya M Nasrallah; David A Wolk
Journal:  J Nucl Med       Date:  2014-11-20       Impact factor: 10.057

Review 4.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 5.  Systematic review of the diagnostic utility of SPECT imaging in dementia.

Authors:  Jing Ming Yeo; Xuxin Lim; Zubair Khan; Suvankar Pal
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-06       Impact factor: 5.270

6.  Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.

Authors:  Christian Habeck; Shannon Risacher; Grace J Lee; M Maria Glymour; Elizabeth Mormino; Shubhabrata Mukherjee; Sungeun Kim; Kwangsik Nho; Charles DeCarli; Andrew J Saykin; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

Review 7.  Neuroimaging in Frontotemporal Lobar Degeneration: Research and Clinical Utility.

Authors:  Sheena I Dev; Bradford C Dickerson; Alexandra Touroutoglou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  Dementia spectrum disorders: lessons learnt from decades with PET research.

Authors:  Heather Wilson; Gennaro Pagano; Marios Politis
Journal:  J Neural Transm (Vienna)       Date:  2019-02-14       Impact factor: 3.575

9.  Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways.

Authors:  Connie J Liou; Ming Tong; Jean P Vonsattel; Suzanne M de la Monte
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

10.  Reference cluster normalization improves detection of frontotemporal lobar degeneration by means of FDG-PET.

Authors:  Juergen Dukart; Robert Perneczky; Stefan Förster; Henryk Barthel; Janine Diehl-Schmid; Bogdan Draganski; Hellmuth Obrig; Emiliano Santarnecchi; Alexander Drzezga; Andreas Fellgiebel; Richard Frackowiak; Alexander Kurz; Karsten Müller; Osama Sabri; Matthias L Schroeter; Igor Yakushev
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.